State of Wisconsin Investment Board acquired a new position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 15,000 shares of the biotechnology company’s stock, valued at approximately $407,000. State of Wisconsin Investment Board owned approximately 0.06% of Aclaris Therapeutics at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the company. Nationwide Fund Advisors boosted its position in shares of Aclaris Therapeutics by 8.3% during the 1st quarter. Nationwide Fund Advisors now owns 6,627 shares of the biotechnology company’s stock worth $198,000 after purchasing an additional 510 shares in the last quarter. American International Group Inc. boosted its position in shares of Aclaris Therapeutics by 31.3% during the 1st quarter. American International Group Inc. now owns 6,804 shares of the biotechnology company’s stock worth $203,000 after purchasing an additional 1,623 shares in the last quarter. UBS Group AG boosted its position in shares of Aclaris Therapeutics by 60.4% during the 1st quarter. UBS Group AG now owns 4,462 shares of the biotechnology company’s stock worth $133,000 after purchasing an additional 1,681 shares in the last quarter. Alliancebernstein L.P. boosted its position in shares of Aclaris Therapeutics by 24.0% during the 1st quarter. Alliancebernstein L.P. now owns 9,300 shares of the biotechnology company’s stock worth $277,000 after purchasing an additional 1,800 shares in the last quarter. Finally, TD Asset Management Inc. boosted its position in shares of Aclaris Therapeutics by 15.6% during the 2nd quarter. TD Asset Management Inc. now owns 17,100 shares of the biotechnology company’s stock worth $464,000 after purchasing an additional 2,304 shares in the last quarter. 95.79% of the stock is currently owned by institutional investors.

ACRS has been the topic of a number of research analyst reports. Cantor Fitzgerald initiated coverage on shares of Aclaris Therapeutics in a research report on Friday, June 16th. They set an “overweight” rating and a $50.00 price objective on the stock. Jefferies Group LLC reissued a “buy” rating and set a $36.00 price objective on shares of Aclaris Therapeutics in a research report on Wednesday, June 28th. ValuEngine cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, June 6th. Guggenheim reissued a “buy” rating and set a $40.00 price objective on shares of Aclaris Therapeutics in a research report on Tuesday, July 4th. Finally, BidaskClub raised shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, July 24th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $40.00.

In related news, Director Andrew N. Schiff purchased 108,601 shares of Aclaris Therapeutics stock in a transaction that occurred on Wednesday, August 16th. The shares were bought at an average price of $23.02 per share, for a total transaction of $2,499,995.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 16.30% of the stock is owned by insiders.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) opened at 26.95 on Thursday. The company’s market cap is $720.54 million. The company has a 50-day moving average of $26.44 and a 200 day moving average of $27.77. Aclaris Therapeutics, Inc. has a 12 month low of $20.15 and a 12 month high of $33.25.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.12. On average, equities analysts forecast that Aclaris Therapeutics, Inc. will post ($3.10) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.dailypolitical.com/2017/09/14/state-of-wisconsin-investment-board-invests-407000-in-aclaris-therapeutics-inc-acrs.html.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.